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a b s t r a c t
Stem cells serve as potential therapeutics due to their high proliferative capacity, low immunogenic reac-
tivity and their differentiating capabilities. Several pre-clinical and early-stage clinical studies are carried
out to treat genetic diseases, cancers and neurodegenerative disorders with promising preliminary
results. However, there are still many challenges that scientists are trying to overcome such as the
unclear expression profile of stem cells in vivo, the homing of stem cells to the site of injury and their
potential immune-reactivity. Prospective research lies in gene editing of autologous stem cells in vitro
and safe injection of these modified cells back into patients. Here, we review the clinical trials executed
using stem cell therapy in an attempt to cure challenging diseases like cancer, Parkinson’s and
Alzheimer’s diseases.
 2018 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research & Technology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427
2. Stem cells in treatment of the disease of the century . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
2.1. Stem cell-mediated suicide gene therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
2.2. Stem cells as delivery vehicles for oncolytic viruses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
2.3. Stem cells role in post-cancer treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
2.4. Potentiating the effect of stem cell-based therapy in fighting cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428
3. Stem cells against neurodegenerative disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
3.1. Stem cell therapy for Parkinson’s disease (PD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
3.2. Stem cell therapy for Alzheimer’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 429
4. Challenges facing stem cell therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430
1. Introduction
Stem cell therapy is emerging profoundly, raising hopes for cur-
ing diseases that were once thought to be incurable. Founding con-
cepts behind the use of stem cells in therapy include their ability to
https://doi.org/10.1016/j.jgeb.2018.09.002
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regenerate original body tissues, their ability to be modified to
deliver potent drugs or nanomaterials, and their immune modula-
tion capability [1].
According to the National Cancer Institute, it is estimated that
1,735,350 new cases of cancer will be diagnosed in 2018 in the
US and 609,640 patients will die from cancer [2]. Scientists spare
no effort to deeply understand the biology of tumors to develop
new cancer treatments. However, major challenges include insuffi-
cient and unspecific delivery of drugs to target sites, in addition to
their short half-lives [3]. Stem cell therapy has recently arisen as a
promising means to tackle such challenges.
Slowly progressive, degenerative neurological diseases such as
Parkinson’s disease (PD) and Alzheimer’s disease (AD) elicited the
urge for novel therapeutics. Research in the last couple of years
was shifted towards transplant therapy for these diseases and stem
cells therapy is emerging to alleviate symptoms or even reverse
disease progression [4–6]. Here, we review the latest stem cell
therapy advances in treatment of cancer, Parkinson’s disease and
Alzheimer’s disease.
2. Stem cells in treatment of the disease of the century
Scientists have employed different strategies to make use of
stem cells in combating cancer. For example, stem cells were mod-
ified to express anti-cancer effector proteins such as pro-apoptotic
and anti-proliferative proteins or express anti-angiogenesis factors
to limit cancer cells’ blood supply and create a non-supportive
microenvironment for the tumor [7–9]. Other strategies include
modification of stem cells such as Mesenchymal Stromal/Stem
Cells (MSCs) that naturally show tumor-tropic properties, to stim-
ulate the immune response against cancer [10]. For example,
human MSCs were modified to secrete IL-12 and IL-18, shifting
the immune response against cervical cancer, renal cell carcinoma
and glioblastoma in mice through the activation of natural killer
cells and tumor-specific T cells [11–14].
2.1. Stem cell-mediated suicide gene therapy
An interesting strategy to achieve cancer cell death involves
genetic engineering of stem cells to express specific enzymes that
convert inactive forms of anti-cancer drugs into their active forms
only at the tumor site. This strategy that confers high specificity
and efficacy is known as stem cell-mediated suicide gene therapy.
Three main suicide gene systems are utilized: (1) Conversion of
5-fluorocytosine (5-FC) to the toxic anti-metabolite 5-fluorouracil
(5-FU) via cytosine deaminase (CD) enzyme, (2) Conversion of
the inactive Irinotecan drug to the topoisomerase inhibitor SN-38
by carboxylesterase enzyme, (3) Conversion of the Ganciclovir
(GCV) drug to its phosphorylated forms to block DNA synthesis
through the action of the thymidine kinase enzyme.
The three systems have been used to modify MSCs, and showed
efficacy in treatment of brain, breast, ovarian and prostate cancers
in mouse models [10,15–17]. In another study, neural stem cells
were modified to express the CD enzyme in addition to IFN-b that
induces apoptosis. The cells were then injected in mice with meta-
static breast cancer and subsequently, the inactive 5-FC prodrug
was injected to the mice. Results showed that the combined treat-
ment suppressed the growth and metastasis of the cancer cells
[18]. Moreover, 18 patients with high-grade glioma were enrolled
in a clinical trial that has started in 2014 and is expected to be
complete by 2019. The tumors were surgically resected and the
patients’ brains were injected with neural stem cells which were
modified to express the CD enzyme. After a few days of the cellular
injection, the patients were treated with 5-FC, which was then con-
verted into 5-FU (Clinicaltrials.gov, NCT02015819).
2.2. Stem cells as delivery vehicles for oncolytic viruses
Oncolytic viruses confer selectivity to tumors since they repli-
cate within cancer cells only. However, the host immune system
rapidly recognizes the virus and clears it, reducing its therapeutic
efficacy. Stem cells have been studied as potential delivery vehicles
for these viruses, showing promising results in pre-clinical studies.
MSCs have been used as effective carriers of attenuated oncoly-
tic viruses to hepatocellular carcinoma and ovarian tumors in mice
and humans, respectively [19,20]. MSCs selectively localized to the
tumor xenografts in mice and infection of tumor cells with the
viruses was subsequently confirmed. Tumor volumes were signifi-
cantly reduced and the survival rate of mice increased remarkably
[21]. In 2014, MSCs were loaded with oncolytic Herpes Simplex
Virus (oHSV) which increased the anti-tumor efficacy of the virus
in a mouse model of glioblastoma compared to the direct injection
of the oHSV [10,22].
In a study performed in 2010, researchers explored the efficacy
and safety of injecting autologous MSCs, which were genetically
modified to carry oncolytic adenovirus (ICOVIR-5), in four young
patients who suffered from metasatatic neuroblastoma. Fortu-
nately, one case out of the four showed no evidence of metastatic
disease and was in remission for three years post-treatment [23].
The first oncolytic virus accepted by the FDA was the Talimo-
gene Laherparepvec (Imlygic), or T-VEC which was used for the
treatment of melanoma [24]. Since the microenvironment of
tumors is relatively ‘‘cold”; lacking immune cells, it has been
recently postulated that the oncolytic viruses can induce a sys-
temic immune response through secreting danger signals. These
signals turn the local microenvironment of tumors into hot areas
of immune cells recruitment [25,26]. For example, pre-surgical
treatment with oncolytic viruses was shown to sensitize triple-
negative breast and brain cancer cells to immunotherapy [27,28].
Moreover, a recent clinical study showed that combining T-VEC
oncolytic virotherapy with immunotherapy increased the infiltra-
tion of T cells to the tumor vicinity [29].
2.3. Stem cells role in post-cancer treatment
In hematological cancers, bone marrow transplantation is a
conventional protocol used to restore the cellular components of
the blood after chemotherapy rounds. However, a major drawback
associated with the use of bone marrow transplantation is the
development of immune reactions such as graft-versus-host dis-
ease (GvHD) [30]. This immune condition is treated with immuno-
suppressive drugs, which unfortunately have adverse effects and
can be toxic to patients [31,32]. It was shown that MSCs suppress
lymphocyte proliferation, manifesting immune suppressive prop-
erties and thus, they are being tested as co-therapy with Hemato-
poeitic Stem Cells (HSCs) to prolong the graft survival of the HSC
transplant. The MSCs immunomodulatory mechanisms include
inhibition of T cell proliferation and induction of T regulatory cells
[33]. In addition, it has been shown that MSCs provide a cellular
support for the HSCs niche [34]. In a phase I/II clinical trial assess-
ing the effect of MSCs on GvHD acute and chronic cases, complete
response was achieved in one acute and one chronic case, partial
response was achieved in six acute and three chronic cases, and
no major adverse effect was observed after MSCs therapy [35].
2.4. Potentiating the effect of stem cell-based therapy in fighting
cancer
Despite the promise that stem cell-based cancer therapy holds
in cancer treatment, some challenges still exist. For instance, the
use of allogenic cells can mount severe host immune response, lim-
iting their therapeutic potential. In 2013, a group of researchers
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managed to edit HLA genes in human Embryonic Stem Cells
(hESCs) in vitro using zinc-finger nucleases, enabling the ESCs to
evade the HLA-restricted cytotoxic T-lymphocytes. This paved
the road towards generating universal cells from allogenic donors
[36]. Also, in a study in 2014, CTLA4-Ig fusion protein and PD-L1
were knocked in hESCs to allow for their constitutive expression
before and after differentiation. The knock-in of CTLA4-Ig disrupts
the co-stimulatory pathways and that of PD-L1 activates the inhi-
bitory pathways of T cells. Therefore, the modified hESCs were
immune-protected when injected into humanized mice. These
humanized mice were reconstituted with a human immune sys-
tem that normally elicits an immune reaction against hESCs. This
finding can lead to developing ways to protect hESCs from allo-
genic immune rejection without the need for systemic immune
suppression [37].
The tumor environment is a heterogeneous pool of cells baring
different mutations. In addition, cancer cells tend to gain resistance
to therapies, which adds up to the complication of fighting cancer
with a single type of therapy [10,38]. Therefore, the need for com-
binatorial therapy arises. As previously discussed, the combinato-
rial therapy strategies could include combination of
immunotherapy with oncoloytic virotherapy [18]. Other strategies
include combining radiotherapy, chemotherapy and oncolytic
virotherapy [10,39,40].
3. Stem cells against neurodegenerative disorders
3.1. Stem cell therapy for Parkinson’s disease (PD)
PD is the second most common neurodegenerative disease, that
affects 2–3% of the elder population PD is characterized by the loss
of dopaminergic nigral neurons, formation of a-synuclein-
containing Lewy bodies and extensive extra-nigral pathology
[41–43]. Its symptoms include motor and non-motor features
[44] that respond well to dopaminergic agents in the early stages.
However, these medications fail overtime and produce adverse
effects, such as dyskinesia and neuropsychiatric complications
[45].
In 1987, a team led by professor Madrazo recognized neural
grafting as a novel approach for replacing lost dopaminergic cells.
Adrenal medulla tissues were autografted into the brain of two
young PD patients, which led to the amelioration of PD signs
including tremors, rigidity and akinesia. Neural transplantation
and cell-based therapy have, since then, been considered as possi-
ble therapies for PD since it is a good candidate as a focal degener-
ation disorder [46]. This study was supported by a pilot study held
2 years later on 18 patients confirming Madrazo’s results. How-
ever, this approach was stopped due to limited pre-clinical data
and patients developing post-operative psychiatric disturbances
[47].
Studies on neural transplantation continued during the 90s
but were conducted using different source of cells: fetal ventral
mesencephalic (fVM) instead of adrenal medulla. Earlier studies
showed promising results; however, the technique wasn’t yet
optimized [47]. In 1993, the NIH funded two trials, where the
enrolled patients with moderately advanced PD were grafted
with human fVM. The results were published in 2001 followed
by another one in 2003 conducted as a double blind placebo
control trial [48,49]. Both trials reached the same conclusion that
human fVM transplants didn’t ameliorate the symptoms of PD
compared to the dopaminergic medications, in addition, the
patients exhibited Graft-Induced Dyskinesia (GIDs) [50–52].
Although in these trials some of the subjects showed encourag-
ing signs of improvement, the consensus at that time was to
discard this approach.
New approaches were pursued to find better source of cells for
transplantation. The emergence of human embryonic stem cells
(hESCs) in 1998, unlocked the scope for several research teams to
generate dopaminergic neurons [53–55] that functioned in vitro
or in animal models of PD [48,56–58]. Although hESCs provided
unlimited source of cells, they failed to produce proper midbrain
dopamine (DA) neurons resulting in little improvement in addition
to tumor formation in incompletely differentiated cells [59,60].
The failure of hESCs was owed to the fact that the DA neurons
have been erroneously generated. This was discovered in 2007
and 2008, when two studies reported that the DA neurons are
not derived from neuroepithelial cells like all neurons but from a
different source of cells [61,62]. This insight inspired researchers
to develop new hESCs differentiation protocols to generate the cor-
rect DA neurons [63–66]. Hence, the floor-plate-derived cells
expressed specific markers of midbrain DA neurons, released dopa-
mine and restored the motor functions after transplantation into
rodent models of PD similar to that attained by human fetal DA
neurons [64,66,67].
Clinical trials with stem cell (PSC)-derived DA neurons have
witnessed a new and an exciting era of stem cell-based therapy
for Parkinson’s disease. Therefore, guidelines and strategies were
set for clinical translation to patients [68–70]. For instance, in
2018, a group of Chinese researchers could transplant neural-
precursor cells derived from embryonic stem cells in PD patients.
In this trial, the cells are intended to develop into mature
dopamine-producing neurons [71]. Also, Australia have witnessed
the world-first neural stem cell transplant by lead researcher Dr
Andrew Evans, Royal Melbourne Hospital (RMH) Neurologist, and
his team. Tens of millions of parthenogenetic neural stem cells
were transplanted directly into the brains of 12 Australian patients
suffering from moderate to severe PD as part of a phase I safety
clinical study (Clinicaltrials.gov, NCT02452723).
The generation of the induced Pluripotent Stem Cells (iPSCs) by
Takahashi and Yamanaka, provided a source of patient-specific and
disease-specific neurons and avoided many of the ethical issues
associated with the hESC lines [72,73]. Although there is a vast
development in iPSC research, a recent commentary discussed
the major shift in the main goals of iPSC research from personal-
ized cell therapy to a tool for mechanistic studies of human dis-
eases [74]. That is the reasons why clinical trials using iPSCs are
scarce.
In 2017, Kikuchi et al., a Japanese team established a successful
protocol for transforming iPSCs derived from both healthy individ-
uals and PD patients, into dopamine-producing neurons. They
grafted human iPSC-derived midbrain dopaminergic progenitors
into monkeys that had been treated with 1-methyl-4-phenyl-1,2,
3,6-tetrahydropyridine (MPTP), a toxin which ablates nigral
dopaminergic neurons. They continued to monitor their behavior
for two years in an attempt to alleviate PD symptoms [75]. A major
boost to researchers’ hope was attained as the monkeys survived
with improved motor function and crucially no signs of tumor
development for both sets of cells: derived from healthy individu-
als and PD patients [75]. These results fortified the confidience of
this team to test this approach on humans.
3.2. Stem cell therapy for Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder, affecting more than 46.8 million elders above the age of
65 worldwide. AD is considered the main cause of dementia. It is
associated with impairments of memory, thinking, language, and
reasoning [76–79]. AD is considered challenging as it involves
extensive attacks on neurons in the brain [80]. The accumulation
of Amyloid beta (Ab peptides), lipid-carrier protein apolipoprotein
E (apoE), microtubule associated protein Tau, and the presynaptic
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protein a-synuclein are enumerated as the prominent neuropatho-
logical symptoms of the AD [79,81–83]
As a result of the significant neuronal loss in the brain at the
time of diagnosis, the treatment interventions for AD patients with
the available drugs are considered too late. Therefore, new phar-
maceuticals that target earlier stages before widespread neurode-
generation and overt dementia occur, are crucially needed [84].
Despite the long-term focus on the pathology of AD, still no effi-
cient treatment that can stop or reverse the progression of the dis-
ease is present. Moreover, symptomatic treatments are modestly
effective and offer only temporary benefit. In this view, the stem
cell therapy such as ESC or iPSC-derived neural cells emerged from
the early 2000s as a potential idea to replace destroyed neurons
beyond the aid of pharmacological therapies [85].
Stem cell therapy as an approach to treat AD was first tested on
animal models [84]. Neural stem cells (NSCs) is an example of cell
therapy derived from ESCs, which aims to restore the function of
the damaged nervous system. For example, NSCs derived from
neonatal rats’ hippocampus were implanted into the brain of AD
rats and were able to differentiate into the new cholinergic neu-
rons and improved the ability of spatial learning and memory for
AD rodent models [86]. Also, neuron-like cell (NLC)-derived mouse
embryonic stem cells (mESCs) that were injected into AD rats
resulted in the repair of brain lesions [87].
Human NSCs (hNSCs) were also transplanted intra-
cerebroventricular in transgenic AD mice models to ensure the
wide spread of the engrafted cells to repair the multiple affected
regions of the brain [88,89]. The study revealed migration, engraft-
ment and differentiation of hNSCs into three CNS neural cell types.
The developed synaptic plasticity and anti-apoptotic function, also
decreased tau-phosphorylation, Ab production, and neuroinflam-
mation. The transgenic mice showed long term survival, no adverse
effects were shown and the mice had an improved spatial memory.
However, the cognitive recovery following hNSC grafting was not
maintained in the long term [89]. These results were further
proved in a similar study where the cognitive function of the mice
was improved through synaptogenesis [88,89].
In addition, scientists transplanted human umbilical cord mes-
enchymal stem cell-derived neuron-like cells (HUMSC-NCs);
another stem cell source into AD mice. This activated microglia
(M2-like microglia) and its associated anti-inflammatory and
immune-modulatory responses that beneficially enhanced the
cerebral function, augmented synapsin I level, and reduced Ab
deposition in the mice [90]. In another study, systemic transplan-
tation of bone marrow-derived mesenchymal stem cells in AD
mice showed reduction in pE3-Ab plaque size and an immune-
modulation effect [91]. Also, MSCs could be used for modulating
adult neurogenesis endogenously, since co-culturing of Ab-
treated neuronal progenitor cells (NPCs): an AD disease model
with MSCs stimulated hippocampal neurogenesis and enhanced
NPCs differentiation into mature neurons [92]. Furthermore,
placenta-derived mesenchymal stem cells improve memory dys-
function in an Ab1-42-infused mouse model of AD [93]. AD mice
models were also transplanted with precursors of cholinergic neu-
rons which were derived from human iPS (hiPS) cells. The mice
survived and showed improved memory function [94].
Owing to the promising results manifested in the pre-clinical
trials executed on AD animal models using MSCs, they were suffi-
cient to approve the initiation of clinical trials in patients with AD.
A phase 1 clinical trial using human umbilical cord blood–derived
mesenchymal stem cells (hUCB-MSCs) was first conducted in 2015
on nine patients with mild-to-moderate AD. In an attempt to treat
AD, the patients were stereo-tactically injected with hUCBMSCs
into the hippocampus and precuneus: the brain parts mostly
affected during the earlier phases of AD. It was proven that the
administration method of the stem cells was safe, practicable
and showed no adverse effects; however, it should be further
tested for its clinical effectiveness on AD pathogenesis. The study
paved a new road for future AD cell therapies studies using larger
sample size and placebo controls to test the efficacy of this treat-
ment in the long term [95].
Several clinical trials are being conducted on AD patients and
their results are yet to be published (Clinicaltrials.gov,
NTC01547689, NTC02672306, NTC02054208, and NTC02600130).
However, all these trials are limited by the diversity of the damage
in the neurons of AD patients.
The most recent phase I/II clinical trial that started in 2017, is
held by the biotechnology enterprise Nature Cell. It is conducted
on 60 AD patients using ‘ASTROSTEM’: a stem cell drug for AD
treatment which consists of stem cells derived from autologous
adipose tissue and intravenously injected ten times into the
patients (200 million cells/injection) (Clinicaltrials.gov,
NCT03117738).
4. Challenges facing stem cell therapy
Although stem cells hold great promise in therapeutics, it is
necessary to provide scientific evidence on the safety and effective-
ness of their usage [96]. Moreover, several challenges are yet to be
overcome in order to translate experimental lab studies into clini-
cal applications [10]. One challenge that scientists face is the abil-
ity to correctly isolate and identify stem cells from the patients’
tissues [97]. Stem cells need to be expanded on a large-scale to
have a significant efficacy when injected into patients. The expan-
sion and passaging of the cells might affect their phenotype and
render the pool of the cells heterogeneous in their properties,
which adds more challenge to systemize any genetic manipulation
[98]. The stem cells also need to differentiate properly into the
required cell type in vitro and maintain their cellular identity when
transferred into patients; express the same genomic and metabolic
profile [96].
Other issues include the use of viral vectors to integrate
pluripotency genes into differentiated cells to reprogram them,
which may increase the risk of tumor formation [99]. Thus, the
safety of the oncolytic viruses carried on stem cells need to be well
studied to avoid any complications in its clinical studies [10]. In
addition, the epigenetic memory of the differentiated cell may con-
fer repressive epigenetic mark that may not allow for the expres-
sion of the reprogramming factors [100]. Another issue is the
difference between the niche of the host cells and that of the
in vitro cultured cells, which decreases the proliferative and differ-
entiating capacity [96]. Another major challenge is the immune
rejection, where transplanted stem cells can mount severe host
responses [101]. Finally, treatment of complicated diseases such
as cancer or neurodegenerative disorders requires targeting multi-
ple defective pathways simultaneously which hints at the neces-
sity to search for combinatorial therapies. Selection of the right
therapies to combine is still a big challenge that remains to be
addressed [10].
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